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Abstract Poly(ethylene glycol)-phosphatidylethanolamine
(PEG-PE) conjugates have been introduced in liposomal
compositions. The resulting large unilamellar vesicles were
subjected to the action of phospholipase C. Enzyme-promoted
vesicle aggregation and fusion were assayed in liposomes
containing various proportions of PEG-PE. At PEG-PE
concentrations above 1 mol% the rate of phospholipid hydrolysis
decreases, perhaps because the PEG moiety hinders the enzyme
from reaching the membrane surface. At concentrations above
0.1 mol% vesicle aggregation occurs at a slower rate, presumably
because of the repulsive barrier properties or surface-grafted
PEG. Lipid mixing decreases in parallel with vesicle aggrega-
tion. Finally, liposomal fusion rates measured as mixing of
vesicle aqueous contents are decreased at or even below 0.1
mol%. The latter inhibition is due, apart from the reduced rates
of lipid hydrolysis, vesicle aggregation and lipid mixing, to a
PEG-PE-based stabilization of the lipid bilayer structure. Thus
the observed low rates of contents mixing arise from three
combined and independent inhibitory effects of PEG-PE.
z 1997 Federation of European Biochemical Societies.
1. Introduction
Poly(ethylene glycol) (PEG)-derivatized phosphatidyletha-
nolamines (PEG-PE) have been used in liposomal formula-
tions for clinical use in the last decade, with the aim of re-
ducing liposomal uptake by the mononuclear phagocytic
system, thus increasing the vesicle lifetimes in circulation [1^
5]. From the early studies, the membrane stabilizing proper-
ties of PEG-PE were thought to parallel those of the ganglio-
side GM1 [6], both being molecules with a phospholipid moi-
ety and a large polar headgroup. Mori et al. [7] described that
both PEG-PE and GM1 prolonged the circulation time of
liposomes, although only the former lipid showed a signi¢cant
steric barrier activity, as judged from liposome agglutination
studies.
As a part of a wider project on the structural e¡ects of
phospholipase C on lipid bilayers, we have recently examined
the e¡ects of a variety of gangliosides, including GM1, on the
phospholipase C-promoted fusion of liposomes [8]. Two dif-
ferent inhibitory e¡ects of gangliosides on the fusion process
were described, namely inhibition of the enzyme phosphohy-
drolase activity and inhibition of the lamellar to non-lamellar
transition of the lipid structures. In view of the similarities,
both in structure and in liposome stabilizing properties, be-
tween gangliosides and PEG-PE, we tested the in£uence of the
latter compound on the phospholipase C-induced fusion proc-
ess mentioned above. Although the overall e¡ect of PEG-PE
on liposomal fusion is inhibitory, just as that of gangliosides,
some additional mechanisms appear to operate in PEG-PE
inhibition. In particular, the steric barrier e¡ect of surface-
grafted PEG inhibits vesicle aggregation even with intact
phospholipase C activities. As a result, the phenomena of
phospholipid hydrolysis and liposome aggregation, that had
been conceptually distinguished and causally related in our
previous papers [9^11] are now physically separated.
2. Materials and methods
PEG-PE (MW of PEG W2000) was purchased from Avanti (Bir-
mingham, AL). This particular molecular weight of PEG was selected
according to the data of Mori et al. [7]. Phospholipase C (EC 3.1.4.1)
from Bacillus cereus was supplied by Boehringer Mannheim. All lipids
were from Lipid Products (South Nut¢eld, UK). Fluorescent probes
were purchased from Molecular Probes (Eugene, OR).
The methods have been described in detail in our previous publi-
cations. Brie£y, large unilamellar vesicles (LUV) were prepared by the
extrusion method of Mayer et al. [12]. The lipid composition of these
liposomes was PC/PE/Ch (2:1:1 mol ratio). When required, the ap-
propriate amounts of PEG-PE were added. These amounts are indi-
cated as additional mole percentages. The aqueous lipid suspensions
were extruded through Nuclepore ¢lters, 0.1-Wm pore diameter.
Phospholipase C activity was determined from measurements of
water-soluble phosphorous, and vesicle aggregation was estimated
by the increase in scattered light [9,10]. Lipid mixing was measured
by dilution in the bilayer of the self-quenching probe octadecylrhoda-
mine B (R18), as described by Hoekstra et al. [13]; (see for details
[8,9]). Mixing of aqueous vesicle contents was estimated using the
ANTS/DPX £uorescent probe system described by Ellens et al. [14]
(details as in [8,9]).
Steady-state £uorescence anisotropy of TMA-DPH was recorded in
a MPF-66 Perkin Elmer £uorometer as described by Nieva et al. [15].
Lamellar to non-lamellar transitions were recorded as shown by Ba-
sa
è
nìez et al. [16].
31
P-NMR spectra were recorded in a KM360 Varian
spectrometer operating at 300 MHz for protons; the spectra were
plotted with a line broadening of 80 Hz [8,16].
3. Results
3.1. PEG-PE and liposomal fusion
The inhibitory e¡ect of 1 mol% PEG-PE on the phospho-
lipase C-promoted liposomal fusion is shown in Fig. 1. The
e¡ect on vesicle aggregation and lipid mixing consists of de-
creasing the maximum rates while keeping constant saturation
values (saturation not shown for lipid mixing in Fig. 1A). The
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inhibitory e¡ect of 1% PEG-PE on liposomal fusion (mixing
of aqueous contents) is particularly remarkable (Fig. 1B).
Note that, unlike in our previous studies with fusion inhibi-
tors, PEG-PE is inhibiting fusion without altering the rate of
phospholipid hydrolysis.
The e¡ects of PEG-PE at concentrations ranging from 0.1
to 9% are shown in Fig. 2 for lipid hydrolysis, vesicle aggre-
gation, lipid mixing and mixing of vesicle aqueous contents.
The minimum concentration of PEG-PE that has a detectable
e¡ect varies according to the e¡ects observed. The threshold
appears to be above 1 mol% for phospholipid hydrolysis (Fig.
2A), at 0.5 mol% for vesicle aggregation (Fig. 2B), between
0.1 and 0.5 mol% for lipid mixing (Fig. 2C), and at or even
below 0.1 mol% for contents mixing (Fig. 2D). Thus the more
complex the event, the lower the threshold concentration of
PEG-PE; in increasing order of sensitivity, enzyme activi-
ty 6 aggregationW lipid mixing 6 contents mixing. This sug-
gests that a number of independent inhibition mechanisms are
accumulating their e¡ects along the process. The observations
in Fig. 2 are con¢rmed and clari¢ed by the data in Table 1,
that summarizes the maximum rates for each process in the
presence of increasing concentrations of PEG-PE. The data in
Table 1 show more accurately that vesicle aggregation may be
already partially inhibited at 0.5% PEG-PE. Also noticeable is
the parallel inhibition of aggregation and lipid mixing, sug-
gesting that PEG-PE does not prevent lipid mixing once the
liposomes are in contact.
3.2. PEG-PE and lipid phase behaviour
We have recently shown that measurements of TMA-DPH
£uorescence polarisation could be used to detect lamellar to
nonlamellar phase transitions in lipid systems [16]. In view of
the putative involvement of nonlamellar intermediates in
membrane fusion ([11], and references therein), and of the
role of gangliosides in stabilizing lamellar phases [8], we tested
the e¡ect of PEG-PE on the lamellar to nonlamellar transi-
tion(s) of PC/PE/Ch/diacylglyceride through changes in TMA-
DPH £uorescence polarisation. Parallel studies were carried
out with
31
P-NMR.
The data in Fig. 3A,B correspond respectively to the mix-
tures PC/PE/Ch/diacylglyceride 50:25:25:5 and 50:25:25:10
(mol ratios). According to changes in TMA-DPH £uorescence
anisotropy, these mixtures have a phase transition at 57³C
and 48³C, respectively [16]. Similar measurements have been
carried out with the above lipid mixtures, to which increasing
amounts of PEG-PE (0.5^9 mol%) have been added. It is clear
that the PEG-PE conjugate stabilizes the lamellar phase, shift-
ing to higher temperatures the phase transition to the point
that, in some cases, the mixture remains lamellar in the whole
temperature range of our study, i.e. up to 80³C (Fig. 3A).
These results were fully con¢rmed by
31
P-NMR spec-
troscopy. As an example, Fig. 4 shows spectra corresponding
to a PC/PE/Ch/diacylglyceride (50:25:25:5) mixture, in the
absence (control) or presence of 1% PEG-PE. The control
mixture exhibits a lamellar to nonlamellar transition, that is
FEBS 18864 12-9-97
Table 1
Percent inhibitory e¡ect of PEG-PE on the rates of phospholipase C activity, vesicle aggregation, lipid mixing, and vesicle fusion (mixing of
aqueous contents)
% PEG-PE Hydrolisis rate Aggregation rate Lipid mixing rate Fusion rate
0 100 100 100 100
0.1 99 103 ND 80
0.5 105 95 82 25
1 103 83 63 5
3 80 23 16 1
6 28 3.5 2.5 0
9 9 0 ND 0
The original mixture (0% PEG-PE) contains PC/PE/Ch (2:1:1). The data are taken from experiments as shown in Fig. 2; the ¢gures are average
values of three experiments.
ND, not determined.
Fig. 1. PEG-PE inibition of phospholipase C-promoted vesicle fu-
sion. Control: large unilamellar vesicles consisting of PC/PE/Ch
(2:1:1 mol ratio). PEG-PE: plus 1 mol% PEG-PE conjugate. A:
Continuous lines, vesicle aggregation; broken lines, lipid mixing. B:
Continuous lines, mixing of vesicle aqueous contents (fusion); (a)
% diacylglycerol production, control; (b) % diacylglycerol produc-
tion in the presence of 1 mol% PEG-PE.
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perfectly detectable at 60³C by the presence of an isotropic
signal as the main feature in the spectral line. At 70³C, any
remnants of a bilayer signal have disappeared, and the spec-
tral lineshape shows a combination of isotropic and hexagonal
components. In the presence of 1 mol% PEG-PE, the lamellar
phase is very e¡ectively stabilized, since it is shown to prevail
even at 70³C. According to our previous studies [8,11,16], the
observed stabilization of the lamellar phase by PEG-PE ex-
plains the di¡erence between the inhibition caused by this
reagent on vesicle aggregation (+lipid mixing) and the one
caused on mixing of vesicle aqueous contents.
4. Discussion
The stability provided by PEG-PE to cell and model mem-
branes has been described by a number of authors [5,7,17^20].
In particular, inhibition of membrane fusion has been men-
tioned as one of the e¡ects of surface-grafted PEG [21,22].
Ka
ë
sbauer et al. [23] have described an interesting system in
which PEG-PE inhibits PEG-induced liposomal fusion. How-
ever, the results in this paper present a more detailed descrip-
tion of the inhibitory e¡ects of PEG-PE on the various steps
leading to bilayer fusion.
4.1. The steps of membrane fusion and levels of fusion
inhibition
It has become apparent in the recent years, as a result of
multiple experimental studies on cell and model membranes,
that the process of membrane fusion is in fact the result of at
least three events, namely membrane apposition, mixing of
lipids in the outer bilayers and (through the establishment
of a fusion structural intermediate) full lipid mixing with mix-
ing of aqueous contents [24]. Among other laboratories, we
were able to show, with free poly(ethylene glycol) and soni-
cated vesicles of egg phosphatidylcholine, that di¡erent PEG
concentrations were required to reach the various stages men-
tioned above [25], thus contributing to support the idea that
those stages, periods or steps had each its separate physical
entity, being more than ideal concepts. Much of the work
behind these ideas has been reviewed in Bentz [26]. In the
model system for membrane fusion that has been explored
by this group in the past years, namely phospholipase C-in-
duced liposome fusion, the hydrolytic action of the enzyme is
a sort of `zeroth stage' that brings about the remaining ones
[9,10,27].
In our recent study on fusion inhibition by gangliosides [8]
we were able to distinguish two levels of inhibition, respec-
tively the `phosphohydrolase activity' and the `lamellar to
nonlamellar transition' levels, at which gangliosides acted in-
dependently and additively. This was already a step forward
with respect to our previous observations on fusion inhibition
(e.g. by lysophospholipid [10]) in which only inhibition of the
¢nal event, i.e. contents mixing, was considered. In the present
work, the use of PEG-PE has allowed us to distinguish a
further level of inhibition, namely membrane apposition (or
vesicle aggregation), as separate from phospholipid hydroly-
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C
Fig. 2. Correlation among PEG-PE inhibition of (A) phosphohydro-
lase activity, (B) vesicle aggregation, (C) lipid mixing, and (D) con-
tents mixing, induced by phospholipase C. Control: as in Fig. 1.
The ¢gures by the curves correspond to the PEG-PE concentrations
in the bilayers (as mol%).
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sis, that had not been observed as a separately regulable entity
in this series of studies up to now.
The results summarized in Table 1 show that PEG-PE is
inhibiting every step involved in liposome fusion. However,
the inhibitory e¡ect is not the same on every stage examined.
The enzyme phosphohydrolase activity is clearly inhibited at
PEG-PE concentrations above 1% (mol ratio). This inhibition
can be reasonably attributed to either, or both, of two factors.
First, PEG-PE may be inhibiting phospholipase C in much
the same way as gangliosides, either by modifying the catalytic
activity of the adsorbed enzyme or by altering the availability
of substrates in an appropriate conformation [8,28]. The in-
hibitory e¡ect of gangliosides on phospholipases A
2
and C
increases with the complexity of the polar head group [29^
31], in this respect PEG-PE o¡ers a particularly large head
group. But PEG-PE may be operating as well through a sec-
ond mechanism, namely by hindering enzyme access to the
vesicle surface. Torchilin et al. [32] have presented theoretical
and experimental arguments in support of the idea that even
low proportions of PEG-PE (in the 0.2^1 mol% range) may
prevent opsonizing protein molecules from contacting the lip-
osomes. For the same reason PEG-PE would prevent access
of phospholipase C to its substrate, causing an apparent en-
zyme inhibition.
In another recent study [33] the origin of the lag time that is
observed when phospholipase C is added to LUV consisting
of pure egg phosphatidylcholine was examined. It was con-
cluded that, irrespective of the experimental conditions, the
end of the lag time was concomitant with the start of vesicle
aggregation, so that the `burst' of enzyme activity was virtu-
ally coincident with the increase in turbidity due to liposome
aggregation. In previous papers [10,11] we had proposed that
formation of diacylglycerol patches on the liposomal surface,
as a result of phospholipase C activity, lead almost necessarily
to liposome aggregation. In all of our previous experiments,
changes in enzyme activity were invariably linked to parallel
changes in aggregation rate. PEG-PE allows us the opportu-
nity to dissect these two phenomena. While it will be interest-
ing to examine the e¡ect of this conjugate on the enzyme lag
period, the data in Table 1 show clear divergences between the
e¡ects of PEG-PE on lipid hydrolysis and vesicle aggregation
rates. At 1 mol%, PEG-PE does not inhibit enzyme activity,
while the aggregation rate is reduced by about 20%. At 3%
PEG-PE, enzyme activity is only inhibited by 20%, and the
aggregation rate is decreased by 80%. These data show that,
in addition to inhibiting phospholipase C, PEG-PE is impair-
ing membrane apposition through an independent mecha-
nism, so that the observed low rates of aggregation are the
result of two added inhibitory events. It has been known for
several years that PEG-PE provides a strong repulsive barrier,
of steric origin, that prevents the close approach of bilayers,
according to X-ray di¡raction studies [17], and also prevents
agglutination of immunoliposomes [7]. The same mechanism
is probably preventing LUV aggregation in our case, even in
the presence of diacylglyceride. Holland et al. [21] have de-
scribed the inhibition by PEG-PE of Ca
2
-induced fusion of
liposomes containing phosphatidylserine. Inhibition was at-
tributed to the steric barrier e¡ect of PEG-PE. Note that these
authors did not perform direct measurements of vesicle aggre-
gation, but only of lipid mixing (through a resonance energy
transfer procedure).
When the data in Table 1 corresponding to vesicle aggre-
gation and lipid mixing are compared, a good parallelism is
observed. This would suggest that PEG-PE had no direct
e¡ect on the mixing of lipids, and that the inhibition of the
latter event was a direct consequence of decreased vesicle ag-
gregation. These data con¢rm for our system what had been
implied by Holland et al. [21] in their case, i.e. that inhibition
of lipid mixing was only a result of the steric barrier e¡ect.
Note however that a direct inhibition of lipid mixing by PEG-
PE cannot be entirely ruled out in the light of the present
experiments.
In the last step of fusion communication is established be-
tween the cavities of the apposed vesicles, and their contents
are allowed to mix. Comparison of the columns correspond-
ing to lipid mixing and contents mixing in Table 1 again
shows an additional inhibitory mechanism that prevents con-
tents mixing even with reasonable rates of lipid mixing. The
situation is reminiscent of the one found for ganglioside in-
hibition [8] and, as shown in Figs. 3 and 4, the same explan-
ation applies here: PEG-PE, just as gangliosides, stabilizes the
lamellar phase, thus preventing the formation of the highly-
curved intermediate that, according to the currently accepted
theories [34,35], is required in the last step of fusion. Holland
et al. [36] have shown a similar bilayer-inducing behaviour of
PEG-PE for a di¡erent lipid system (dioleoylphosphatidyl-
ethanolamine/cholesterol).
In summary, PEG-PE has three independent e¡ects that
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Fig. 3. Thermotropic phase transitions of phospholipid/cholesterol
aqueous dispersions as detected by changes in anisotropy of TMA-
DPH. The ¢gures by the curves correspond to the concentration of
PEG-PE in the bilayer (expressed as mol%) in each case. The basic
lipid mixtures (0%) were (A) PC/PE/Ch/diacylglycerol (50:25:25:5,
mol ratio) and (B) PC/PE/Ch/diacylglycerol (50:25:25:10, mol ra-
tio).
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may act together inhibiting phospholipase C-induced lipo-
some fusion, namely inhibition of enzyme activity, prevention
of membrane apposition and stabilization of the lamellar
phase. The last two e¡ects should operate in any membrane
fusion system.
From the point of view of liposome stability in blood, the
observations in this paper add a new factor explaining the
stabilizing properties of PEG-PE, namely its phospholipase-
inhibiting ability. The similar e¡ects of PEG-PE and ganglio-
sides on phospholipase C (this paper, and also Basa
è
nìez et al.
[8]) suggest that a variety of lipases may be inhibited similarly
by PEG-PE as they are by gangliosides [28], the conjugate
thus contributing signi¢cantly to an increased vesicle lifetime
in biological £uids.
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